Bivatuzumab
Humanized (from mouse) | |
|---|---|
| Target | CD44 v6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| (verify) | |
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]
It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer".[3] Prior to 2002 it was described as targeting CD44 v8.[4]
It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer.[1]
It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.
References
- ^ PMID 14530488.
- PMID 14506195.
- ^ "Amendments to Previous Lists". WHO Drug Information. 16 (3). 2002.
- ^ "Recommended INN: List 45" (PDF). WHO Drug Information. 15 (1): 4. 2001.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |